NLRP6 and colorectal carcinoma: Recently, it has been demonstrated that NLRP6 and IL-18, alone or in combination, are powerful predictors of patient outcomes in colorectal disease, and examining the epithelial inflammasomes may improve clinical decisions for more reliable prognostic evaluations and recognize novel therapeutic purposes in CRC.